TABLE 1.
Baseline demographic and clinical characteristics of the SOT and HC groups
| Characteristics | SOT recipients (N = 54) | HC (N = 26) |
|---|---|---|
| Mean age (SD) — years | 72.1 (3.6) | 62.4 (6.7) |
| Male sex — number (%) | 33 (61.1) | 9 (34.6) |
| Race and ethnicity— number (%) | ||
| White non-Hispanic | 48 (88.9) | 23 (88.5) |
| Other non-Hispanic | 6 (11.1) | 3 (11.5) |
| Mean body mass index (SD) — kg/m2 | 28.1 (5.4) | 27.7 (5.6) |
| Underlying medical conditions — number (%) | ||
| Any underlying medical condition | 53 (98.2) | 18 (69.2) |
| Hypertension | 47 (87.0) | 8 (30.8) |
| Dyslipidemia | 39 (72.2) | 9 (34.6) |
| Chronic kidney disease | 48 (88.9) | 0 (0.0) |
| Cardiovascular disease | 30 (55.6) | 4 (15.4) |
| Diabetes mellitus | 27 (50.0) | 2 (7.7) |
| Obesity | 17 (31.5) | 7 (26.9) |
| Chronic lung disease | 11 (20.4) | 3 (11.5) |
| Autoimmune disease | 7 (13.0) | 2 (7.7) |
| Malignancy | 6 (11.1) | 0 (0.0) |
| Chronic liver disease | 4 (7.4) | 0 (0.0) |
| Non-immunosuppressive medications — number (%) | 54 (100) | 19 (73.1) |
| Organ type — number (%) | ||
| Kidney | 22 (40.7) | – |
| Liver | 20 (37.0) | – |
| Heart | 6 (11.1) | – |
| Lung | 4 (7.4) | – |
| Kidney and liver | 2 (3.7) | – |
| Immunosuppressive medications — number (%) | ||
| CNI only | 12 (22.2) | – |
| CNI, corticosteroids, and MPA | 12 (22.2) | – |
| CNI and corticosteroids | 11 (20.4) | – |
| CNI and MPA | 9 (16.7) | – |
| CNI, corticosteroids, and azathioprine | 3 (5.6) | – |
| CNI and mTOR inhibitors | 2 (3.7) | – |
| CNI and azathioprine | 4 (7.4) | – |
| CNI, corticosteroids, and mTOR inhibitors | 1 (1.9) | – |
| Median time since transplant (IQR) — years | 7.0 (2.7–13.0) | – |
Abbreviations: CNI, calcineurin inhibitor; HC, healthy control; IQR, interquartile range; mTOR, mammalian target of rapamycin; MPA, mycophenolic acid; SD, standard deviation; SOT, solid organ transplant.